Few studies directly compared drug-eluting stents and bare-metal stents (BMSs) in diabetic patients. DESSERT was an Italian multicenter randomized trial to show the efficacy of sirolimus-eluting stents (SESs) compared with BMSs in de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >= 3 months on top of glycoprotein IIb/IIIa inhibitors. The primary end point was in-stent late lumen loss, assessed using centralized quantitative coronary angiography at 8-month follow-up. Centrally adjudicated composite major adverse cardiac events (MACEs) and target-vessel failure (TVF; death, treated vessel-related acute myocardial infarction, and target-vessel revascularization) at 30 days and 9 and 12 months were secondary end points. Seventy-five patients were randomly assigned to an SES (109 lesions), and 75 (109 lesions), to a BMS. The 2 groups were well balanced for clinical, anatomic, and procedural characteristics. In-stent late lumen loss decreased from 0.96 +/- 0.61 nun for BMSs to 0.14 +/- 0.33 for SESs (p < 0.001), and in-segment binary restenosis was 38.8% versus 3.6%, respectively (p < 0.001). Twelve-month clinical events were significantly lower in the sirolimus group: MACEs 22.1 % versus 40% (p = 0.023), target-lesion revascularization 5.9% versus 30% (p < 0.001), and TVF 14.7% versus 34.3% (p = 0.008). At multivariate analysis, stent type was confirmed as an independent predictor of in-segment late loss (p < 0.001), binary restenosis (p < 0.001), 12-month TVF (p = 0.010), and 12-month MACEs (p = 0.037). In conclusion, the randomized DESSERT showed SESs to be safe and effective in decreasing both angiographic parameters of restenosis and incidence of MACEs compared with BMSs in diabetic patients with de novo 1- or 2-vessel coronary stenoses. (c) 2008 Elsevier Inc. All rights reserved.

Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian multicenter randomized DESSERT study) / Aleardo, Maresta; Elisabetta, Varani; Marco, Balducelli; Ferdinando, Varbella; Corrado, Lettieri; Lucia, Uguccioni; Pietro, Sangiorgio; BIONDI ZOCCAI, Giuseppe; Dessert, Investigators. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - 101:11(2008), pp. 1560-1566. [10.1016/j.amjcard.2008.01.040]

Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian multicenter randomized DESSERT study)

BIONDI ZOCCAI, GIUSEPPE;
2008

Abstract

Few studies directly compared drug-eluting stents and bare-metal stents (BMSs) in diabetic patients. DESSERT was an Italian multicenter randomized trial to show the efficacy of sirolimus-eluting stents (SESs) compared with BMSs in de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >= 3 months on top of glycoprotein IIb/IIIa inhibitors. The primary end point was in-stent late lumen loss, assessed using centralized quantitative coronary angiography at 8-month follow-up. Centrally adjudicated composite major adverse cardiac events (MACEs) and target-vessel failure (TVF; death, treated vessel-related acute myocardial infarction, and target-vessel revascularization) at 30 days and 9 and 12 months were secondary end points. Seventy-five patients were randomly assigned to an SES (109 lesions), and 75 (109 lesions), to a BMS. The 2 groups were well balanced for clinical, anatomic, and procedural characteristics. In-stent late lumen loss decreased from 0.96 +/- 0.61 nun for BMSs to 0.14 +/- 0.33 for SESs (p < 0.001), and in-segment binary restenosis was 38.8% versus 3.6%, respectively (p < 0.001). Twelve-month clinical events were significantly lower in the sirolimus group: MACEs 22.1 % versus 40% (p = 0.023), target-lesion revascularization 5.9% versus 30% (p < 0.001), and TVF 14.7% versus 34.3% (p = 0.008). At multivariate analysis, stent type was confirmed as an independent predictor of in-segment late loss (p < 0.001), binary restenosis (p < 0.001), 12-month TVF (p = 0.010), and 12-month MACEs (p = 0.037). In conclusion, the randomized DESSERT showed SESs to be safe and effective in decreasing both angiographic parameters of restenosis and incidence of MACEs compared with BMSs in diabetic patients with de novo 1- or 2-vessel coronary stenoses. (c) 2008 Elsevier Inc. All rights reserved.
2008
01 Pubblicazione su rivista::01a Articolo in rivista
Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian multicenter randomized DESSERT study) / Aleardo, Maresta; Elisabetta, Varani; Marco, Balducelli; Ferdinando, Varbella; Corrado, Lettieri; Lucia, Uguccioni; Pietro, Sangiorgio; BIONDI ZOCCAI, Giuseppe; Dessert, Investigators. - In: THE AMERICAN JOURNAL OF CARDIOLOGY. - ISSN 0002-9149. - 101:11(2008), pp. 1560-1566. [10.1016/j.amjcard.2008.01.040]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/434063
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 37
social impact